Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
This study looks at the effect on basal and pentagastrin-stimulated acid output of 40 mg
Esomeprazole (Nexium) administered orally and intravenously as a 15-minute infusion to people
with symptoms of Gastroesophageal Reflux Disease (GERD)